Citigroup started coverage on shares of Legend Biotech (NASDAQ:PLRX) in a report released on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $40.00 price objective on the stock.
Separately, Piper Sandler initiated coverage on shares of Legend Biotech in a research note on Monday. They issued an overweight rating and a $50.00 target price for the company.
PLRX opened at $29.53 on Monday. Legend Biotech has a 1 year low of $21.05 and a 1 year high of $35.63.
Pliant Therapeutics, Inc, a biotechnology company, discovers, develops, and commercializes treatments for fibrotic diseases. The company focuses on tissue-specific integrin modulation and EMT inhibition fibrosis diseases in lungs, liver, muscle, kidney, skin, heart, and the gastrointestinal tract. Its pipeline includes PLN-74809, an inhibitor of aVß1/aVß6 for idiopathic pulmonary fibrosis and primary sclerosing cholangitis; and PLN-1474, an inhibitor of TGF-ß activation by the integrin aVß1 for the treatment of end-stage liver fibrosis in NASH.
Recommended Story: Outstanding Shares
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.